SLV308 for Treatment of Patients With Early Parkinson's Disease
NCT ID: NCT00269516
Last Updated: 2008-08-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
468 participants
INTERVENTIONAL
2006-06-30
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
pardoprunox
fixed dose 6 mg
2
Pardoprunox
fixed dose 12 mg
3
Pardoprunox
12-42mg
4
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pardoprunox
fixed dose 6 mg
Pardoprunox
fixed dose 12 mg
Pardoprunox
12-42mg
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Early stage of disease, Modified Hoehn \& Yahr up to stage III,
* UPDRS motor score (part III) 10 at baseline.
Exclusion Criteria
* Patients who have undergone surgery for the treatment of PD,
* Presence of dyskinesias,
* Motor fluctuations or loss of postural reflexes,
* Clinically significant abnormalities,
* Patients treated with L-dopa or dopamine agonists currently or in the past (for more than 3 months in total),
* Antipsychotic.
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Solvay Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Solvay Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Director Solvay
Role: STUDY_DIRECTOR
Solvay Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site 284
Huntsville, Alabama, United States
Site 274
Little Rock, Arkansas, United States
Site 283
Fountain Valley, California, United States
Site 277
La Jolla, California, United States
Site 271
San Francisco, California, United States
Site 279
Fort Lauderdale, Florida, United States
Site 293
Gainsville, Florida, United States
Site 282
Port Charlotte, Florida, United States
Site 285
Sunrise, Florida, United States
Site 273
Tampa, Florida, United States
Site 290
Chicago, Illinois, United States
Site 280
Kansas City, Kansas, United States
Site 292
Bingham Farms, Michigan, United States
Site 275
Traverse City, Michigan, United States
Site 276
St Louis, Missouri, United States
Site 287
St Louis, Missouri, United States
Site 278
Las Vegas, Nevada, United States
Site 286
Rochester, New York, United States
Site 288
Ashville, North Carolina, United States
Site 289
Charlotte, North Carolina, United States
Site 294
Toledo, Ohio, United States
Site 281
Pittsburgh, Pennsylvania, United States
Site 291
Warwick, Rhode Island, United States
Site 272
Houston, Texas, United States
Site 201
Buenos Aires, , Argentina
Site 202
Buenos Aires, , Argentina
Site 203
Buenos Aires, , Argentina
Site 204
Buenos Aires, , Argentina
Site 206
Buenos Aires, , Argentina
Site 208
Capital Federal, CBA, , Argentina
Site 207
Ciudad de Buenos Aires, , Argentina
Site 205
Córdoba, , Argentina
Site 100
Brussels, , Belgium
Site 101
Genk, , Belgium
Site 102
Wilrijk, , Belgium
Site 107
Plovdiv, , Bulgaria
Site 103
Sofia, , Bulgaria
Site 104
Sofia, , Bulgaria
Site 105
Sofia, , Bulgaria
Site 106
Sofia, , Bulgaria
Site 268
Barrie, , Canada
Site 260
Calgary, , Canada
Site 264
Greenfield Park, , Canada
Site 263
Markham, , Canada
Site 261
Ottawa, , Canada
Site 266
Ottawa, , Canada
Site 262
Québec, , Canada
Site 265
Québec, , Canada
Site 269
Saskatoon, , Canada
Site 267
Toronto, , Canada
Site 213
Providencia, , Chile
Site 211
San Miguel, , Chile
Site 210
Santiago, , Chile
Site 212
Valdivia, , Chile
Site 221
Bogotá, , Colombia
Site 223
Bogotá, , Colombia
Site 224
Bogotá, , Colombia
Site 222
Cali, , Colombia
Site 220
Medellín, , Colombia
Site 111
Rijeka, , Croatia
Site 112
Split, , Croatia
Site 110
Zagreb, , Croatia
Site 113
Zagreb, , Croatia
Site 114
Zagreb, , Croatia
Site 123
Kuopio, , Finland
Site 122
Lappeenranta, , Finland
Site 120
Oulun Yliopisto, , Finland
Site 121
Tampere, , Finland
Site 124
Turku, , Finland
Site 196
Bangalore, , India
Site 194
Hyderabaad, , India
Site 193
Mumbai, , India
Site 195
Mumbai, , India
Site 199
New Delhi, , India
Site 198
Thiruvananthapuram, , India
Site 197
Visakhapatnam, , India
Site 131
Haifa, , Israel
Site 132
Petah Tikva, , Israel
Site 133
Ramat Gan, , Israel
Site 130
Tel Aviv, , Israel
Site 232
Aguascalientes, , Mexico
Site 230
Guadalajara - Jalisco, , Mexico
Site 231
Monterrey N.L., , Mexico
Site 233
Tlalpan, , Mexico
Site 191
Christchurch, , New Zealand
Site 190
Wellington South, , New Zealand
Site 244
Barrios Altos-Lima, , Peru
Site 241
La Victoria-Lima, , Peru
Site 240
Lima, , Peru
Site 243
San Isidro-Lima, , Peru
Site 242
Surco-Lima, , Peru
Site 143
Brasov, , Romania
Site 140
Bucharest, , Romania
Site 141
Craiova, , Romania
Site 142
Mures, , Romania
Site 158
Kazan', , Russia
Site 150
Moscow, , Russia
Site 151
Moscow, , Russia
Site 154
Moscow, , Russia
Site 156
Moscow, , Russia
Site 152
Saint Petersburg, , Russia
Site 157
Saint Petersburg, , Russia
Site 159
Saint Petersburg, , Russia
Site 155
Smolensk, , Russia
Site 153
Yaroslav, , Russia
Site 160
Belgrade, , Serbia
Site 161
Belgrade, , Serbia
Site 162
Belgrade, , Serbia
Site 163
Niš, , Serbia
Site 170
Bratislava, , Slovakia
Site 171
Bratislava, , Slovakia
Site 174
Levice, , Slovakia
Site 173
Nitra, , Slovakia
Site 172
Žilina, , Slovakia
Site 250
Cape Town, , South Africa
Site 252
Cape Town, , South Africa
Site 251
Durban, , South Africa
Site 253
Gauteng, , South Africa
Site 254
Pretoria, , South Africa
Site 127
Gothenburg, , Sweden
Site 126
Norrköping, , Sweden
Site 125
Stockholm, , Sweden
Site 180
Kharkiv, , Ukraine
Site 183
Kharkiv, , Ukraine
Site 181
Kyiv, , Ukraine
Site 182
Kyiv, , Ukraine
Site 185
Lviv, , Ukraine
Site 184
Vinnytsia, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sampaio C, Bronzova J, Hauser RA, Lang AE, Rascol O, van de Witte SV, Theeuwes AA; Rembrandt/Vermeer Study Groups. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. Mov Disord. 2011 Jul;26(8):1464-76. doi: 10.1002/mds.23590. Epub 2011 May 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S308.3.001
Identifier Type: -
Identifier Source: org_study_id